USA flag logo/image

An Official Website of the United States Government

Evaluation of a synthetic anti-GPI vaccine candidate in severe anemia models of…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93422
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI082878
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANCORA PHARMACEUTICALS, INC.
ANCORA PHARMACEUTICALS, INC. 200 BOSTON AVENUE, STE 4975 MEDFORD, MA 99999-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Evaluation of a synthetic anti-GPI vaccine candidate in severe anemia models of m
Agency: HHS
Contract: 1R43AI082878-01
Award Amount: $530,977.00
 

Abstract:

DESCRIPTION (provided by applicant): Plasmodium falciparum malaria afflicts up to 10% of the global population, resulting in over 600 million infections and two to three million deaths annually. Malaria-related fatalities arise predominantly from two clini cally defined complications associated with severe disease: cerebral malaria (CM) and severe malaria anemia (SMA). Substantial scientific evidence indicates that severe malarial disease results from the downstream effects of a toxin generated by the malari a parasite. This toxin, a glycolipid termed glycosylphosphatidylinositol (GPI), leads to excessive inflammatory cytokine production and, hence, the clinical manifestations observed in both CM and SMA. Published pre-clinical studies demonstrate that the gly can (carbohydrate) portion of the GPI can provide immunoprotection against CM caused by a malaria species within an established murine model. Recently, rodent models for SMA have been developed, which parallel the SMA clinically observed in humans upon mal aria infection. Moreover, the models display one or both of the anemia forming mechanisms observed in human clinical disease: uninfected red blood cell clearance and erythropoietic suppression. The overall goals of this proposal are: to evaluate if immuniz ation towards the GPI glycan can confer protection against SMA in the recently developed animal models, to identify a lead product candidate to move into development, and to begin to validate anemia as a potential clinical endpoint in detailed anemia chara cterization studies. PUBLIC HEALTH RELEVANCE: Ancora Pharmaceuticals Inc. is developing a novel vaccine against malaria. Severe anemia is a major complication due to malaria infection, especially in young children. This proposal aims to provide key proof-o f-concept data that the anti-toxin vaccine approach may protect against severe malaria anemia.

Principal Investigator:

A. S. Campbell
7813957700
SCAMPBELL@ANCORAPHARMA.COM

Business Contact:

John Pena
jpena@ancorapharma.com
Small Business Information at Submission:

ANCORA PHARMACEUTICALS, INC.
ANCORA PHARMACEUTICALS, INC. 200 BOSTON AVENUE, STE 4975 MEDFORD, MA 02155

EIN/Tax ID: 470877050
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No